Ann: Non-binding term sheet signed with BioCryst, page-25

$50k to do DD for acquisition.
Surely once they do the DD, they would know pretty well what the drug can achieve. Why not then offer them a cash payout in cash and equity tranches that is escrowed for 2 years?? If the drug doesn't fit acquiring outright it's not worth it anyway...

Instead, this deal is let me do all the capital work and we'll give you a fat commission for doing nothing.
This is what makes me feel this was an underwriter lead deal which wouldn't equate to anything but an attempt to create a liquidity event.

Management need to focus on ISLA101 and ignore the noise of brokers adding pressure for silly deals for news flow. If ISLA101 is successful, liquidity will come and LT holders will be rewarded which I'm confident will be a revenue generating machine as it would be the only ingestible solution on the market.